{"id":"guabenxan","rwe":[{"pmid":"6751915","year":"1982","title":"[Double-blind controlled study of the therapeutic effectiveness and tolerance of the guabenxan-bemetizid combination as compared with guanethidine-hydrochlorothiazide in arterial hypertension in the aged].","finding":"","journal":"Giornale di clinica medica","studyType":"Clinical Study"}],"tags":[{"label":"guabenxan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"tensigradyl","offLabel":[],"synonyms":["guabenxan sulfate","tensigradyl","guabenxan","guabenzodioxan"],"timeline":[],"approvals":[],"brandName":"Tensigradyl","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"guabenxan","explanation":"Imagine your body's cells are like a city, and Tensigradyl is a key that unlocks a specific door to allow the right things to happen. By binding to these molecules, Tensigradyl helps to restore balance and normal function to the cells, which can help to treat various diseases.","oneSentence":"Tensigradyl works by binding to specific biological molecules to produce a therapeutic effect.","technicalDetail":"Tensigradyl is a small molecule that interacts with specific biological targets, likely through reversible binding, to produce its therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1332","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUABENXAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:48:43.982955","biosimilars":[],"competitors":[],"genericName":"guabenxan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"SAW16W26X6","CHEBI":"CHEBI:134872","INN_ID":"3544","UMLSCUI":"C0617438","ChEMBL_ID":"CHEMBL2105111","PUBCHEM_CID":"28563","MESH_SUPPLEMENTAL_RECORD_UI":"C036327"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1982 Apr","pmid":"6751915","title":"[Double-blind controlled study of the therapeutic effectiveness and tolerance of the guabenxan-bemetizid combination as compared with guanethidine-hydrochlorothiazide in arterial hypertension in the aged].","journal":"Giornale di clinica medica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tensigradyl (GUABENXAN) is a small molecule drug in the guabenxan class, but specific details about its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further information about its pharmacokinetic properties, such as half-life and bioavailability, is not available. The current owner and generic manufacturers of Tensigradyl are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}